Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Oligodendroglioma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Glioblastoma (234)

Astrocytoma (74)

Glioblastoma (234)

Astrocytoma (74)

›

IDH2 mutation	Oligodendroglioma	IDH2 mutation	Oligodendroglioma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH1 mutation	Oligodendroglioma	IDH1 mutation	Oligodendroglioma	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1	vorasidenib Sensitive: A1 - Approval vorasidenib Sensitive : A1
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2